Rat Model Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application, Service, Technology, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Rat Model Market size was assessed at USD 1.86 billion in 2026 and is poised to grow at a 6.75% CAGR between 2027 and 2036, exceeding USD 3.57 billion by 2036. The industry revenue for 2027 is calculated at USD 1.97 billion.
Get more details on this report
Request Free Sample ReportRat Model Market Intelligence Snapshot
Regional Market Dynamics
- North America leads through strong biomedical research infrastructure, pharmaceutical activity, and consistent demand for rat models in preclinical studies.
- Asia Pacific is expanding at an 8.14% CAGR, supported by rising research capacity, biopharmaceutical development, and life sciences investment.
Segment Momentum
- Pharmaceutical & Biotechnology Companies held a 40.08% share in 2026 due to their extensive use of rat models in drug discovery, preclinical validation, and safety assessments integrated into internal R&D programs.
- Immunology is the fastest-growing application as researchers increasingly rely on rat models to study complex immune responses and disease pathways that are difficult to replicate using simpler systems.
Market Expansion Drivers
- Increasing pharmaceutical R&D and drug discovery activities driving demand for preclinical rat models.
- Advances in CRISPR and genetic engineering enabling development of customized disease-specific rat models.
- Growing use of transgenic rat models improving accuracy of human disease simulation in biomedical research.
Leading Market Participants
- Key companies in the rat model market include Charles River Laboratories International, Inc. (United States), Taconic Biosciences, Inc. (United States), Envigo RMS LLC (United States), genOway S.A. (France), Janvier Labs (France), Inotiv, Inc. (United States), Trans Genic Inc. (Japan), Biomere Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.86 billion
- 2027 Estimated Market Size: USD 1.97 billion.
- Projected Market Size: USD 3.57 billion by 2036
- Growth Forecast: 6.75% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Pharmaceutical & Biotechnology Companies (End-use) | Toxicology (Application) | Breeding (Service) | Embryonic Stem Cell (Technology) | Outbred (Type)
- Emerging Opportunity Segment: CROs (End-use) | Immunology (Application) | Cryopreservation (Service) | Embryonic Stem Cell (Technology) | Knockout (Type)
Market Growth Drivers and Industry Trends
Increasing pharmaceutical R&D and drug discovery activities driving demand for preclinical rat models
The expansion of pharmaceutical research and drug discovery programs will drive the rat model market growth by increasing the need for reliable preclinical models to evaluate drug efficacy, safety, pharmacokinetics, and disease mechanisms. Rats are widely used in biomedical research because their physiological characteristics support the investigation of complex biological responses before candidate therapies progress to human studies. As drug developers broaden pipelines across therapeutic areas, demand for standardized and specialized rat models is increasing across pharmaceutical companies, academic institutions, and research laboratories.
Advances in CRISPR and genetic engineering enabling development of customized disease-specific rat models
Technological progress in CRISPR-based gene editing and genetic engineering is enabling researchers to create more precisely tailored disease models, which will propel the rat model market growth. These techniques allow specific genes and biological pathways to be modified to reproduce disease-associated characteristics with greater control, supporting research into inherited disorders, cancer, metabolic conditions, and neurological diseases. Customized models can also help investigators examine disease mechanisms and evaluate targeted therapeutic approaches under experimental conditions that more closely reflect specific human disease phenotypes.
Growing use of transgenic rat models improving accuracy of human disease simulation in biomedical research
The increasing use of genetically modified and transgenic animals is strengthening the relevance of advanced preclinical research platforms, thereby boosting the rat model market demand. Transgenic rats can be developed to express or suppress selected genes, enabling researchers to study biological pathways and disease characteristics that are difficult to reproduce using conventional models. Their application in pharmacology, neuroscience, cardiovascular research, and metabolic studies supports more detailed evaluation of disease progression and therapeutic responses.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing pharmaceutical R&D and drug discovery activities driving demand for preclinical rat models | 2.20% | High | North America, Europe, Asia Pacific | High | Near Term |
| Advances in CRISPR and genetic engineering enabling development of customized disease-specific rat models | 2.00% | High | North America, Europe | High | Mid Term |
| Growing use of transgenic rat models improving accuracy of human disease simulation in biomedical research | 1.80% | High | Global | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the rat model market in 2026, supported by a well-established biomedical research ecosystem, substantial investment in life sciences, and extensive use of laboratory rat models across pharmaceutical, biotechnology, academic, and medical research institutions. The region benefits from strong demand for animal models in drug discovery, toxicology, neuroscience, immunology, and disease research, while sophisticated laboratory infrastructure and established research protocols support consistent adoption. Continued emphasis on translational research and the development of therapies for complex diseases further sustains demand for reliable and genetically characterized rat models.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region, driven by expanding pharmaceutical and biotechnology research capabilities, increasing academic research activity, and growing investments in life sciences infrastructure. Rising research requirements across drug development, disease modeling, and preclinical studies are encouraging broader adoption of laboratory rat models. Improvements in research facilities, growing collaboration between academic and industrial institutions, and expanding domestic pharmaceutical development are also strengthening the regional market. In addition, increasing regulatory attention to research quality and laboratory standards is supporting the adoption of more standardized animal models across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Regulated Research StandardsGermany emphasizes standardized rat models that align with stringent laboratory quality and animal welfare requirements. Researchers increasingly seek reproducible models that support reliable pharmacology, toxicology, and biomedical investigations across regulated research environments.
France 🇫🇷
Academic Research SupportFrance maintains demand for rat models through strong collaboration between public research institutes and life science organizations. The market favors standardized laboratory models that enable reproducible findings while supporting diverse biomedical and pharmaceutical research programs.
Italy 🇮🇹
Preclinical Study ExpansionItaly continues strengthening preclinical research activities across universities and pharmaceutical laboratories. The rat model market reflects growing interest in dependable research models that improve study reproducibility and support efficient therapeutic evaluation before clinical development.
Japan 🇯🇵
Precision Disease ModelingJapan focuses on high-quality rat models for neuroscience, oncology, and regenerative medicine research. The country's research community values genetically characterized models that enhance experimental consistency and facilitate the evaluation of novel therapeutic candidates.
South Korea 🇰🇷
Biotechnology Validation PlatformSouth Korea continues expanding biomedical research capabilities, increasing demand for specialized rat models in drug discovery and laboratory studies. Institutions prioritize models that integrate efficiently with advanced research technologies and support consistent experimental validation.
United States 🇺🇸
Translational Research FocusThe U.S. rat model market is supported by extensive preclinical research across pharmaceutical, biotechnology, and academic institutions. Organizations in the U.S. prioritize validated disease-specific models that improve translational outcomes and strengthen confidence in early-stage therapeutic development.
Segment Leadership and Growth Trends
Rat Model Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs CROs (Fastest-Growing Segment)
The pharmaceutical & biotechnology companies segment led the rat model market in 2026, capturing a 40.08% share. Its dominant position is supported by the extensive use of rat models throughout drug discovery, preclinical development, disease research, and therapeutic evaluation. Pharmaceutical and biotechnology organizations rely on these models to study biological mechanisms, assess treatment responses, and generate evidence before progressing candidates through further stages of development. Growing investment in novel therapeutics and the need for reliable preclinical research tools continue to support demand from these end users. The increasing complexity of drug development pipelines also reinforces the importance of specialized rat models capable of supporting targeted disease research and experimental studies.
The CROs segment is expected to be the fastest-growing segment as pharmaceutical and biotechnology companies increasingly outsource preclinical research activities to improve efficiency and access specialized scientific capabilities. Contract research organizations provide expertise, established research infrastructure, and flexible access to diverse animal models, allowing clients to streamline development programs and manage resource requirements more effectively. Rising demand for outsourced toxicology, pharmacology, and disease-modeling studies is supporting greater utilization of rat models within CRO operations. The continued focus on reducing internal research burdens and accelerating development timelines is expected to drive growth in this segment.
Application Segment Analysis: Toxicology (Largest Segment) vs Immunology (Fastest-Growing Segment)
The toxicology segment held the largest share of the rat model market in 2026, accounting for a 35.12% share. Rat models are extensively used in toxicology studies to evaluate the safety profile and potential adverse effects of pharmaceutical compounds, chemicals, and other substances. Their established role in preclinical safety assessment supports their widespread adoption across research programs requiring detailed investigation of dose-related effects and organ-specific responses. Increasing regulatory and scientific emphasis on comprehensive safety evaluation further contributes to the segment's strong position. The development of new therapeutic candidates and continued research into chemical safety are also sustaining demand for toxicology-focused rat models.
The immunology segment is anticipated to be the fastest-growing segment, driven by expanding research into immune-related diseases and the development of therapies designed to modulate immune system activity. Rat models support investigations into immune responses, inflammatory pathways, autoimmune disorders, and the effectiveness of emerging immunotherapies. Growing scientific interest in understanding complex interactions between immune mechanisms and disease progression is increasing the need for specialized research models. As innovation in biologics, targeted therapies, and immune-focused treatment approaches continues to advance, demand for rat models in immunology applications is expected to grow rapidly.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | CROs, Academic and Research Institutes, Pharmaceutical & Biotechnology Companies | Pharmaceutical & Biotechnology Companies | CROs |
| Application | Oncology, Neurology, Immunology, Toxicology, Other | Toxicology | Immunology |
| Service | Cryopreservation, Breeding, Re-derivation, Genetic Testing, Quarantine Depending, Other | Breeding | Cryopreservation |
| Technology | Nuclear Transferase, Microinjection, Embryonic Stem Cell, Others | Embryonic Stem Cell | Embryonic Stem Cell |
| Type | Knockout, Outbred, Inbred, Hybrid, Immunodeficient, Conditioned | Outbred | Knockout |
Competitive Landscape and Market Positioning
Key companies in the rat model market:
1. Charles River Laboratories International Inc. (United States)
2. Taconic Biosciences Inc. (United States)
3. Envigo RMS LLC (United States)
4. genOway S.A. (France)
5. Janvier Labs (France)
6. Inotiv Inc. (United States)
7. Trans Genic Inc. (Japan)
8. Biomere Inc. (United States)
The rat model market is evolving with advancements in genetic research and biomedical experimentation that enable more precise and disease-specific model development. Improved breeding and engineering techniques are enhancing research accuracy and reproducibility. The rat model market continues to support expanding life sciences and pharmaceutical research applications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. (United States) | |||||||
| Taconic Biosciences Inc. (United States) | |||||||
| Envigo RMS LLC (United States) | |||||||
| genOway S.A. (France) | |||||||
| Janvier Labs (France) | |||||||
| Inotiv Inc. (United States) | |||||||
| Trans Genic Inc. (Japan) | |||||||
| Biomere Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| AnthroTek | Jan-26 | AnthroTek has introduced hyper-realistic silicone rat replicas developed via 3D modeling and printing. These physical simulation models are positioned as a strategic alternative to live laboratory animals, aiming to reduce reliance on traditional animal testing in preclinical research and pharmaceutical R&D while maintaining experimental usability for scientific simulation. |
| Taconic Biosciences | Jan-22 | Taconic Biosciences launched the huNOG-EXL humanized immune system (HIS) mouse model. This expansion of the company's research model portfolio is designed to extend the study window for complex immune-oncology research, providing more sophisticated tools for preclinical drug development and advancing competitive capabilities in specialized disease modeling. |
| Inotiv | Nov-21 | Inotiv completed the acquisition of Envigo, a major global provider of research models and services, for approximately USD 271 million. This transaction integrated a proprietary supply of laboratory research models into Inotiv’s existing CRO platform, enabling a vertically integrated discovery-to-approval service model for pharmaceutical and biotechnology clients. |
| The Jackson Laboratory | Oct-21 | The Jackson Laboratory acquired the Japan-based research models and services operations of Charles River Laboratories for USD 63 million. This strategic expansion established The Jackson Laboratory Japan, securing localized production sites and infrastructure to support the company’s distribution and supply of research animal models within the Japanese biomedical research market. |
| Cyagen Biosciences | Mar-20 | Cyagen Biosciences launched a new knockout catalog model, providing a cost-effective and efficient solution for biomedical research. By scaling the availability of these standardized models across U.S. and European markets, the company expanded its service reach and reinforced its position as a competitive provider of genetically modified research models. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Rat Model Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Research Phase | Discovery & Preclinical Research, Toxicology & Safety Assessment, Translational Research, Clinical Trial Support |
| Model Delivery Format | Live Animal Models, Cryopreserved Models, Embryos & Germplasm, Tissue & Biological Samples |
| Commercial Service Model | Custom Model Development, Breeding & Colony Management, Testing & Research Services, Model Licensing |
Rat Model Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Preclinical Research Outsourcing Landscape |
|
| Disease Model Adoption Trends by Therapeutic Area |
|
| Emerging Alternatives to Rat Models and Market Impact |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the rat model market?
How much is the rat model industry expected to grow by 2036?
How is increased pharmaceutical R&D activity influencing demand for rat models?
What role is genetic engineering playing in evolving rat model development?
Why are Pharmaceutical & Biotechnology Companies the largest end users in the rat model market?
Which application segment is growing fastest in the rat model market?
Why does North America remain the leading region for the rat model market?
How is Asia Pacific supporting future growth of the rat model market?
Who are the leading players in the rat model landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization